Evidence map›Paper›PMID 40335788›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Upregulation of MMP9 expression in postradiation angiosarcoma of the breast: a possible predictive risk factor.

Qingqing Ding, Phyu P Aung, Hongxia Sun, Luisa Maren Solis Soto, Wei Lu, Maria Gabriela Raso, Yasmeen Qamar Rizvi, Ignacio I Wistuba, Aysegul A Sahin, Victor G Prieto

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qingqing DingDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Phyu P AungDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Hongxia SunDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Luisa Maren Solis SotoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Wei LuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Maria Gabriela RasoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Yasmeen Qamar RizviDepartment of Investigative Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Ignacio I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Aysegul A SahinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Victor G PrietoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. vprieto@mdanderson.org.ORCID http://orcid.org/0000-0001-9204-7161

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postradiation angiosarcoma of the breast is a secondary angiosarcoma in breast carcinoma patients who have undergone radiation therapy. Although postradiation angiosarcoma is rare, it is very aggressive and has an extremely poor prognosis. Previous studies have implicated matrix metalloproteinase 9 (MMP9) in some cancer development and progression and angiogenesis. In this study, we compared MMP9 expression in surgical specimens from breast cancer patients treated with radiation who did and did not develop breast angiosarcoma within 15 years. We also compared MMP expression in the breast angiosarcoma specimens from patients with postradiation angiosarcoma of the breast and patients with non-breast angiosarcoma not previously treated with radiation. Our results showed that MMP9 was expressed in the endothelial cells in the breast carcinoma specimens from patients who developed angiosarcoma after radiation therapy but not in the breast carcinoma specimens from patients without angiosarcoma. In addition, MMP9 expression was higher in patients with postradiation angiosarcoma of the breast than in patients with non-radiation-associated primary angiosarcomas at non-breast sites. These results suggest that MMP9 may be a risk factor for and play a significant role in the development of postradiation angiosarcoma of the breast.

Indexed as

Biomarkers, TumorBreast NeoplasmsHemangiosarcomaMatrix Metalloproteinase 9Neoplasms, Radiation-InducedAdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMiddle AgedRisk FactorsUp-RegulationBiomarkers, TumorMatrix Metalloproteinase 9MMP9 protein, humanMMP9 expressionPostradiation angiosarcomaRadiation therapy

Identifiers

PMID40335788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.